Genmab — Oktober 2025
-
Epcoritamab as bridging therapy to successful second allogeneic HSCT in relapsed DLBCL after UCBT and CAR T cell therapy https://link.springer.com/article/10.1007/s12185-025-04091-0
-
Afskedssalut fra Novod "Investment case
We believe the Genmab stock is undervalued, both on a DCF valuation and based on
high single-digit to low double-digit P/E multiples in 2026E-27E. We see upside to
our peak sales estimates for Epkinly and Rina-S, and think that Genmab is very well
funded with more than USD 3bn in cash." -
lahn referred to this the other day- The month ahead: November’s upcoming events - Epkinly expansion? https://www.oncologypipeline.com/apexonco/month-ahead-novembers-upcoming-events-0
-
Epkinly Q3 2025 AbbVie 21 + 48 = 69, YTD 190 ( https://news.abbvie.com/2025-10-31-AbbVie-Reports-Third-Quarter-2025-Financial-Results ) (versus Q2 2025 AbbVie 22 + 48 = 70)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind